TelAviv:BLRX

BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADS...

2019-02-08 02:42 2011

BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing...

2019-02-06 00:40 1530

BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants

TEL AVIV, Israel, Feb. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of ...

2019-02-05 06:54 1518